https://www.selleckchem.com/pr....oducts/Vorinostat-sa
All patients were treated with the SAPIEN valve (first generation, XT, or Sapien 3). The TViV procedure was successful in all patients, and no immediate post-replacement paravalvular leak (PVL) or intra-procedural complications were reported. The primary safety and efficacy endpoints were met in all patients. At thirty-days, all patients were alive and reported significant improvements in symptoms and functional status. Transcatheter tricuspid valve implantation is a safe and effective therapy for degenerative tricuspid bioprost
Like
Comment
Share
